Literature DB >> 16799475

Expression of p14ARF, p15INK4b, p16INK4a, and DCR2 increases during prostate cancer progression.

Zhihong Zhang1, Daniel G Rosen, Jorge L Yao, Jiaoti Huang, Jinsong Liu.   

Abstract

Prostate carcinoma is a hormonally driven age-related neoplasm. Cellular senescence is an age-related process where cells remain metabolically active but in a growth-arrested state at the G1 phase. p14(ARF), p15(INK4b), and p16(INK4a), which are known to regulate G1 cell cycle arrest, and the tumor necrosis factor receptor superfamily member decoy receptor 2 (DCR2), have been recently identified as senescence markers. The purpose of this study was to characterize and compare the expression of p14(ARF), p15(INK4b), p16(INK4a), and DCR2 in tissue microarrays containing cases of normal prostate, nodular hyperplasia, prostate intraepithelial neoplasia (PIN), and malignant prostate cancer tissue. We performed immunohistochemical staining for p14(ARF), p15(INK4b), p16(INK4a), and DCR2 in tissue microarray blocks containing 41 cores of normal prostate, 65 cores of nodular hyperplasia, 21 cores of PIN, 69 cores of low-grade prostate carcinoma, and 42 cores of high-grade prostate carcinoma, derived from 80 cases of prostatectomy with adenocarcinomas. We detected positive staining of p16(INK4a) in 19% of the PIN, 25% of the low-grade carcinoma, and 43% of the high-grade carcinoma specimens but none in the normal prostate and nodular hyperplasia specimens. Expression of p14(ARF) revealed very high levels of expression in normal tissues (83%), nodular hyperplasia (88%), PIN (89%), and cancer cells (100%). P15(INK4b) and DCR2 were found positive in 81 and 33% normal, 46 and 10% nodular hyperplasia, 74 and 36% PIN tissues, 87 and 89% low-grade carcinomas, and 100 and 93% high-grade carcinomas. There is an increased protein expression of senescence-associated molecular markers, indicating that cellular senescence might play a role in prostate carcinoma. Because p16(INK4a)-positive cells were detected only in premalignant lesions and carcinomas but not in normal or benign tissues, p16(INK4a) may aid in the diagnosis of PIN and prostate cancer in difficult cases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16799475     DOI: 10.1038/modpathol.3800655

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  26 in total

1.  Transcriptome profiling in oral cavity and esophagus tissues from (S)-N'-nitrosonornicotine-treated rats reveals candidate genes involved in human oral cavity and esophageal carcinogenesis.

Authors:  Ali Khammanivong; Arunkumar Anandharaj; Xuemin Qian; Jung Min Song; Pramod Upadhyaya; Silvia Balbo; Dipankar Bandyopadhyay; Erin B Dickerson; Stephen S Hecht; Fekadu Kassie
Journal:  Mol Carcinog       Date:  2016-01-19       Impact factor: 4.784

2.  Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice.

Authors:  Marianna L Ianzano; Stefania Croci; Giordano Nicoletti; Arianna Palladini; Lorena Landuzzi; Valentina Grosso; Dario Ranieri; Massimiliano Dall'Ora; Ilaria Santeramo; Milena Urbini; Carla De Giovanni; Pier-Luigi Lollini; Patrizia Nanni
Journal:  Oncotarget       Date:  2014-01-15

3.  Expression of p14(ARF), p15(INK4b), p16(INK4a) and skp2 increases during esophageal squamous cell cancer progression.

Authors:  Peng Bai; Xue Xiao; Juan Zou; Lin Cui; Tri M Bui Nguyen; Jinsong Liu; Jianguo Xiao; Bin Chang; Jin Wu; He Wang
Journal:  Exp Ther Med       Date:  2012-03-22       Impact factor: 2.447

4.  Senescence-Like Phenotypes in Human Nevi.

Authors:  Andrew Joselow; Darren Lynn; Tamara Terzian; Neil F Box
Journal:  Methods Mol Biol       Date:  2017

Review 5.  Molecular genetics of prostate cancer: new prospects for old challenges.

Authors:  Michael M Shen; Cory Abate-Shen
Journal:  Genes Dev       Date:  2010-09-15       Impact factor: 11.361

Review 6.  Senescent cells: an emerging target for diseases of ageing.

Authors:  Bennett G Childs; Martina Gluscevic; Darren J Baker; Remi-Martin Laberge; Dan Marquess; Jamie Dananberg; Jan M van Deursen
Journal:  Nat Rev Drug Discov       Date:  2017-07-21       Impact factor: 84.694

Review 7.  Tailoring to RB: tumour suppressor status and therapeutic response.

Authors:  Erik S Knudsen; Karen E Knudsen
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

8.  ARF represses androgen receptor transactivation in prostate cancer.

Authors:  Wenfu Lu; Yingqiu Xie; Yufang Ma; Robert J Matusik; Zhenbang Chen
Journal:  Mol Endocrinol       Date:  2013-02-28

9.  Differential p53-independent outcomes of p19(Arf) loss in oncogenesis.

Authors:  Zhenbang Chen; Arkaitz Carracedo; Hui-Kuan Lin; Jason A Koutcher; Nille Behrendt; Ainara Egia; Andrea Alimonti; Brett S Carver; William Gerald; Julie Teruya-Feldstein; Massimo Loda; Pier Paolo Pandolfi
Journal:  Sci Signal       Date:  2009-08-18       Impact factor: 8.192

10.  Post-translational Down-regulation of Melanoma Antigen-A11 (MAGE-A11) by Human p14-ARF Tumor Suppressor.

Authors:  John T Minges; Gail Grossman; Ping Zhang; Tal Kafri; Elizabeth M Wilson
Journal:  J Biol Chem       Date:  2015-09-01       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.